Zealand Pharma and Boehringer Ingelheim Team Up to Transform Liver Fibrosis Treatment for F2 and F3 Patients
Friday, 7 June 2024, 05:48
Breakthrough Improvement in Liver Fibrosis
Zealand Pharma announces collaboration with Boehringer Ingelheim
- Survodutide shows breakthrough improvement in liver fibrosis
- No worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Zealand Pharma reveals the successful outcome of the latest clinical trials, where survodutide developed in partnership with Boehringer Ingelheim demonstrates remarkable efficacy in treating liver fibrosis, particularly in patients with advanced stages (F2 and F3) without worsening of MASH.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.